TECH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TECH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Bio-Techne's average Accounts Receivable for the three months ended in Mar. 2024 was $218 Mil. Bio-Techne's Revenue for the three months ended in Mar. 2024 was $303 Mil. Hence, Bio-Techne's Days Sales Outstanding for the three months ended in Mar. 2024 was 65.46.
The historical rank and industry rank for Bio-Techne's Days Sales Outstanding or its related term are showing as below:
During the past 13 years, Bio-Techne's highest Days Sales Outstanding was 68.14. The lowest was 47.53. And the median was 62.01.
Bio-Techne's Days Sales Outstanding increased from Mar. 2023 (62.23) to Mar. 2024 (65.46).
The historical data trend for Bio-Techne's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne Annual Data | |||||||||||||||||||||
Trend | Jun14 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | |||||||||||
Days Sales Outstanding | Get a 7-Day Free Trial | 65.88 | 64.24 | 52.52 | 56.11 | 66.31 |
Bio-Techne Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Days Sales Outstanding | Get a 7-Day Free Trial | 62.23 | 65.85 | 69.70 | 68.96 | 65.46 |
For the Biotechnology subindustry, Bio-Techne's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Bio-Techne's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Bio-Techne's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Bio-Techne's Days Sales Outstanding for the fiscal year that ended in Jun. 2023 is calculated as
Days Sales Outstanding (A: Jun. 2023 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Jun. 2022 ) | + | Accounts Receivable (A: Jun. 2023 )) | / | count ) | / | Revenue (A: Jun. 2023 ) | * | Days in Period |
= | ( (194.548 | + | 218.468) | / | 2 ) | / | 1136.702 | * | 365 |
= | 206.508 | / | 1136.702 | * | 365 | ||||
= | 66.31 |
Bio-Techne's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:
Days Sales Outstanding (Q: Mar. 2024 ) | |||||||||
= | Average Accounts Receivable | / | Revenue | * | Days in Period | ||||
= | ( (Accounts Receivable (A: Dec. 2023 ) | + | Accounts Receivable (A: Mar. 2024 )) | / | count ) | / | Revenue (A: Mar. 2024 ) | * | Days in Period |
= | ( (207.451 | + | 227.887) | / | 2 ) | / | 303.428 | * | 365 / 4 |
= | 217.669 | / | 303.428 | * | 365 / 4 | ||||
= | 65.46 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne (NAS:TECH) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Thank you for viewing the detailed overview of Bio-Techne's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Roeland Nusse | director | 473 TENNESSEE, PALO ALTO CA 94306 |
William Geist | officer: PRESIDENT, PROTEIN SCIENCES | 900 MIDDLESEX TURNPIKE, C/O QUANTERIX CORPORATION, BILLERICA MA 01821 |
Charles R. Kummeth | director, officer: Chief Executive Officer | 425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213 |
Shane Bohnen | officer: SVP - General Counsel | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Brenda S. Furlow | officer: SVP - General Counsel | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
John L Higgins | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
Robert V Baumgartner | director | 5775 WAYZATA BOULEVARD, SUITE 400, MINNEAPOLIS MN 55416 |
Kim Kelderman | officer: Pres. Diagnostics & Genom | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Norman David Eansor | officer: SVP Biotech | 8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120 |
James Hippel | officer: Chief Financial Officer | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Joseph D Keegan | director | C/O MOLECULAR DEVICES CORP, 1311 ORLEANS DRIVE, SUNNYVALE CA 94089 |
Alpna Seth | director | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
Julie L Bushman | director | 185 SOUTH 84TH STREET, SUITE 200, MILWAUKEE WI 53214 |
Rupert Vessey | director | C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901 |
Randolph C Steer | director | 614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413 |
From GuruFocus
By PRNewswire • 01-24-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-23-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.